Stephen A. Hill, M.D.

Faraday Pharmaceuticals

Dr. Hill has served as our Chief Executive Officer since August of 2015. He previously served as CEO and President of Targacept, Inc., a biopharmaceutical company developing a diverse pipeline of NNR Therapeutics. In August 2015, Targacept merged with Catalyst Biosciences Inc. Prior to joining Targacept, Dr. Hill served as President of Solvay Pharmaceuticals, Inc. from 2008 to 2010. Solvay was acquired by Abbott Labs in 2010. From 1999 to 2008, Dr. Hill served as President and CEO of ArQule where he successfully implemented the company’s transition from a chemistry services platform to an integrated research and development organization. From 1997 to 1999, Dr. Hill served as Global Head of Clinical Development for Roche Products. He currently serves on the board of directors for publicly held companies Catalyst Biosciences, Cellectar Biosciences, Inc., and Lipocine, Inc. Dr. Hill earned his bachelor and medical degrees from The University of Oxford and practiced medicine in the field of orthopedic surgery prior to his career in the biopharmaceutical industry.


Steven Gillis, Ph.D.

ARCH Venture Partners

Steven Gillis has served as Chairman of our Board of Directors since 2014. Dr. Gillis is a Managing Director with ARCH and joined the firm as a Venture Partner in 2005. Dr. Gillis was a founder and director of Corixa Corp. and served as CEO from its inception and as its Chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, he served as Immunex’s Director of Research and Development, Chief Scientific Officer, and as CEO of Immunex’s R&D subsidiary. Dr. Gillis was interim CEO of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a member of the board until 1997. Dr. Gillis is a director of Bluebird Bio (BLUE), Shire PLC, Pulmatrix, and Accelerator. He serves as director and Chairman of VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines, and PhaseRx. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.


Thomas B. King

Executive Chair, Concentric Analgesics, Inc.

Thomas B. King has been a member of our Board of Directors since 2014.  He has been an independent biotechnology consultant and advisor since 2016.  Previously, Mr. King served as President, CEO and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from 2003 to 2016.  From 2002 to 2003, Mr. King served as President, CEO and a member of the board of directors of Cognetix, Inc., a privately-held biopharmaceutical development-stage company.  From 1994 to 2001, Mr. King held various senior executive positions at Anesta Corporation, a publicly traded pharmaceutical company, including President and CEO from 1997 to 2000, and was a member of the board of directors until Anesta was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company.

Mr. King currently serves on the board of directors of VIVUS, Inc., a publicly-traded biopharmaceutical company, and Concentric Analgesics, Inc., and Satsuma Pharmaceuticals, Inc., both privately-held biotechnology companies.  Mr. King also serves as a mentor at SPIRE Bioventures, a multi disciplinary international consortium aiding biotechnology entrepreneurs, and as an Advisory Board Member of the University of Colorado BioFrontiers Institute. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.


Mark B. Roth, Ph.D. 

Faraday Pharmaceuticals

Mark Roth has served as our President and member of our Board of Directors since the company’s founding in 2014. Dr. Roth is a member of the Division of Basic Sciences at the Fred Hutchinson Cancer Research Center, a position he has held since 1989, and an affiliate professor in the Department of Biochemistry at the University of Washington. He is the founder of Ikaria, Inc., which was formed in 2005. Ikaria was acquired by Mallinckrodt Plc in 2015. Dr. Roth’s pioneering research has included molecular mechanisms of genetic regulation, animal physiology and medical diagnostics. Following his discovery of a class of molecules known as SR proteins, Dr. Roth developed a diagnostic assay for systemic lupus erythematosus, which received FDA approval. He is most noted for his experimental work on new clinical procedures for the temporary reduction of metabolism. In 2007, Dr. Roth was named a MacArthur fellow by the John D. and Catherine T. MacArthur Foundation. In 2007 he also received a Significant Technical Achievement Award from the Defense Advanced Research Projects Agency (DARPA) and in 2006 was an invited speaker at the White House Fellows National Meeting, Washington, D.C. Dr. Roth received a B.Sc. from the University of Oregon and a Ph.D. from the University of Colorado at Boulder.